CD50 Mouse anti-Human, Brilliant Violet 510, Clone: TU41, BD Optibuild
Mouse Monoclonal Antibody
Manufacturer: BD Biosciences 742304
The TU41 monoclonal antibody specifically binds to the intracellular adhesion molecule-3 (ICAM-3) which is also known as CD50. ICAM-3 is a 110-120 kDa type I membrane glycoprotein expressed on all leukocytes (platelets and erythrocytes are ICAM-3-negative). ICAM-3 is also expressed on epidermal Langerhans cells and endothelial cells. It predominantly interacts with LFA-1 (CD11a/CD18) without requiring activation as the initial dendritic cell-T lymphocyte interaction. ICAM-3 is an important LFA-1 ligand that functions in the initiation of the immune/inflammatory response and also plays a role in chemotaxis.The antibody was conjugated to BD Horizon™ BV510 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 405nm and Em Max at 510nm, BD Horizon BV510 can be excited by the violet laser and detected in the BD Horizon V500 (525/50nm) filter set. BD Horizon BV510 conjugates are useful for the detection of dim markers off the violet laser. BV510 is a polymer-based dye that is brighter than BD Horizon V500. Due to similar excitation and emission properties, BD Horizon BV510 and BD Horizon V500 cannot be used simultaneously.
|Aqueous buffered solution containing ≤0.09% sodium azide.|
|ICAM-3, ICAM3, Intercellular adhesion molecule 3|
|Mouse IgG2b, κ|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
|Brilliant Violet 510|
|The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV510 under optimal conditions that minimize unconjugated dye and antibody.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok